- €1.64bn
- -€45.51m
- CH₣112.24m
- 91
- 75
- 17
- 68
Annual income statement for BB Biotech AG, fiscal year end - December 31st, CHF millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 742 | -344 | 1.26 | 0.53 | 112 |
| Cost of Revenue | |||||
| Gross Profit | 741 | -345 | -0.465 | -5.27 | 107 |
| Selling / General / Administrative Expenses | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 50.5 | 61.1 | 359 | 207 | 36.3 |
| Operating Profit | 691 | -405 | -358 | -207 | 76 |
| Net Income Before Taxes | 691 | -405 | -358 | -207 | 76 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 691 | -405 | -358 | -207 | 75.9 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 691 | -405 | -358 | -207 | 75.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 691 | -405 | -358 | -207 | 75.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 12.5 | -7.31 | -6.5 | -3.77 | 1.38 |
| Dividends per Share |